TempraMed Technologies Ltd, a medical technology business, has announced that it has opened an additional U.S. manufacturing facility in Florida.
The additional site expands the Company’s operational capacity and enhances its ability to serve the rapidly growing demand for TempraMed’s temperature-stable medication-storage devices across the United States and globally.
Due to anticipated B2B demand, the new facility will support high-volume production of TempraMed’s core product line-including VIVI Cap™, VIVI Epi™, as well as the upcoming products, including VIVI Box™ smart-storage platform—while enabling improved delivery times, tighter quality control, and increased supply-chain flexibility.
By localising production within the U.S., the company is also positioned to meaningfully reduce cost of goods sold (COGS) through streamlined logistics, reduced import dependencies, and optimised manufacturing workflows.
“Opening a new manufacturing site marks a major step in strengthening our U.S. presence and ensuring we can meet the accelerating needs of healthcare providers, pharmacies, payors, and strategic partners,” said Ron Nagar, CEO of TempraMed.
“Domestic manufacturing gives us the scale, speed, and reliability required to support some of the fastest-growing segments in temperature-sensitive medicine—including GLP-1 therapies, biologics, and self-injectables. It also directly supports our commitment to deliver high-quality, cost-effective solutions that protect patients, reduce waste, and ease the operational burden on health systems.”
The new site will operate alongside TempraMed’s existing global manufacturing network, providing redundancy, efficiency, and a scalable platform for future product introductions. The Company anticipates continued growth in B2B demand as medication manufacturers, distributors, and healthcare systems adopt new standards for in-home and point-of-care temperature management.
“Expanding our U.S. manufacturing footprint strengthens every part of our business—commercialisation, cost structure, and customer satisfaction,” added Nagar. “It positions TempraMed to become the preferred partner for organizations seeking robust, compliant, and sustainable solutions for protecting high-value medications.”
Read more stories like this one on our Leadership channel
